Pharmaceutical Suspension Market Report 2024

This Pharmaceutical Suspension market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The pharmaceutical suspension market size has grown strongly in recent years. It will grow from $54.33 billion in 2023 to $57.38 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth observed during the historic period can be attributed to several factors, an increase in cancer cases, a growing geriatric population, the expansion of home healthcare services, higher per capita healthcare expenditure, and a rise in the number of hospitals.

The pharmaceutical suspension market size is expected to see strong growth in the next few years. It will grow to $71.73 billion in 2028 at a compound annual growth rate (CAGR) of 5.7%. The anticipated growth during the forecast period can be linked to several factors, the rising prevalence of chronic diseases, an increasing need for pediatric and geriatric formulations, growing investment in pharmaceutical research and development, a greater burden of chronic pain, and a higher demand for personalized medicine. Key trends expected during this period include technological advancements, the development of personalized medicine, the use of herbal suspensions, advancements in nanotechnology, and the integration of digital health solutions.

The pharmaceutical suspension market is expected to expand due to the rising prevalence of chronic diseases. Chronic diseases, which are long-term health conditions, stem from factors such as aging populations, poor diets, sedentary lifestyles, genetic predispositions, and environmental influences. Pharmaceutical suspensions offer several advantages for managing chronic diseases, including improved drug delivery for insoluble medications, controlled release, enhanced patient compliance, customizable dosing, and better bioavailability and efficacy for long-term treatment. For example, the National Association of Chronic Disease Directors (NACDD) reported in April 2022 that nearly 60% of American adults have at least one chronic disease, and about 40% have multiple chronic conditions. This prevalence is projected to cost the US economy $2 trillion annually, or $8,600 per person, by 2030. Additionally, the International Diabetes Federation reported in December 2021 that around 537 million adults aged 20-79 had diabetes, with numbers expected to rise to 643 million by 2030 and 783 million by 2045. This increasing prevalence is fueling the growth of the pharmaceutical suspensions market.

Key players in the pharmaceutical suspensions market are advancing medication formulations to improve treatment options and patient outcomes. For instance, electrolyte imbalance liquid medications are designed to correct or manage electrolyte imbalances. In May 2024, ANI Pharmaceuticals Inc., a US-based company, introduced Kionex Suspension, which can be administered orally or rectally. This suspension targets elevated potassium levels by exchanging potassium ions for sodium ions in the gastrointestinal tract. Its liquid form makes it easier for patients who have trouble swallowing tablets, providing controlled and effective potassium removal for managing electrolyte imbalances.

In May 2024, Sun Pharmaceutical Industries Ltd., an India-based specialty pharmaceutical company, acquired Taro Pharmaceutical Industries Ltd. for $347.73 million. This acquisition is intended to enhance Sun Pharma's presence in the pharmaceutical sector, particularly in off-patent pharmaceuticals, prescriptions, and over-the-counter products. Taro Pharmaceutical Industries Ltd., based in Israel, is known for its research-based pharmaceutical manufacturing, including oral suspensions.

Major companies operating in the pharmaceutical suspension market are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Mayo Clinic, Cleveland Clinic, Lonza Group AG, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Glenmark Pharmaceuticals Ltd., ANI Pharmaceuticals Inc., Aristopharma Ltd., Upsher-Smith Laboratories LLC, Padagis LLC, MedEx, Express Pharma, Otsuka Pharmaceutical Co Ltd., Healio, Fluid Handling Inc., Hoffmann-La Roche Ltd., Medthority, SpineThera Inc.

North America was the largest region in the pharmaceutical suspension market in 2023. The regions covered in the pharmaceutical suspension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharmaceutical suspension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pharmaceutical suspension is a liquid dosage form where solid particles are dispersed in a liquid medium without being fully dissolved. This type of formulation allows for controlled release of the active ingredient, which can help achieve targeted therapeutic effects and enhance patient compliance.

Pharmaceutical suspensions come in several types, including oral, parenteral, and others. Oral pharmaceutical suspensions are liquid medications where drug particles are suspended in a liquid for oral intake. They are particularly useful for patients who have difficulty swallowing pills or need precise dosage adjustments. These suspensions are used to treat conditions such as infectious diseases, cancer, gastrointestinal issues, neurological disorders, and more. They are distributed through various channels, including hospital pharmacies, drug stores, retail pharmacies, and online providers. The end-users include hospitals and clinics, home care settings, and other healthcare facilities.

The pharmaceutical suspension market research report is one of a series of new reports that provides pharmaceutical suspension market statistics, including pharmaceutical suspension industry global market size, regional shares, competitors with a pharmaceutical suspension market share, detailed pharmaceutical suspension market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmaceutical suspension industry. This pharmaceutical suspension research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical suspension market consists of sales of pediatric syrups, antacid suspensions, antibiotic suspensions, anti-inflammatory suspensions, and cough and cold formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.